Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Myeloid Leukemia: early-phase trial registry

4 of 7 indexed Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Myeloid Leukemia: 7 US clinical trials tracked, 4 recruiting.

Myeloid Leukemia is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 2 of these trials.

Enrollment posture brief

Registry condition myeloid-leukemia

OPEN 4 | RECR 57% | LATE 0 | EARLY 6 | RANK #2497 | SPON 2

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Myeloid Leukemia (this)57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Myeloid Leukemia

Myeloid Leukemia lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Myeloid Leukemia is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Myeloid Leukemia research.

    University of Colorado, Denver accounts for 2 of 7 trials (28.6%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Myeloid Leukemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 35 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Myeloid Leukemia research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 21

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1

Named interventions

Most-linked intervention names on Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AZD1152 Drug
1 trials
Photography Other
1 trials
Assessment tool IA3-CP without SDoH Other
1 trials
Assessment tool IA3-CP with SDoH Other
1 trials
Nicotinamide Riboside Dietary supplement
1 trials
Mitoxantrone Drug
1 trials
Gilteritinib Drug
1 trials
Blinatumomab Drug
1 trials

US sites by state

Facility locations filed on Myeloid Leukemia trials. A trial with sites in several states counts in each.

Texas 4 trials
Colorado 2 trials
California 2 trials
Washington 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Myeloid Leukemia page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloid Leukemia condition card totals 7 registered trials; most-linked intervention AZD1152; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.